CROSS-DOMAIN PATTERN
Same drug, multiple disease domains
Levetiracetam appears in hypotheses across 3 disease domains: ALS, Alzheimer, Multiple sclerosis. Shared mediators that recur across at least two of those domains: SV2A.
Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.
ALL HYPOTHESES
Repurposing candidates for Levetiracetam
ALS 1
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| Cx43 | ALS | 0.208 | Mid | partial evidence | completed |
Alzheimer 2
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| SV2A | tau hyperphosphorylation | 0.230 | Mid | partial evidence | none | |
| SV2A | cognitive performance | 0.230 | Mid | reproduces known | active |
Multiple sclerosis 1
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| SV2A | synapse density | 0.230 | Mid | novel signal | none |